An observational study in Parkinson Disease, sponsored by Bial - Portela C S.A.. Recruiting at 12 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by Bial - Portela C S.A. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Parkinson Disease by Bial - Portela C S.A. — 1 open to participants now, 2 under way, none of them phase 3. Parkinson Disease · Bial - Portela C S.A..
Among the 60 studies in Parkinson Disease by Bial - Portela C S.A., this one is one of 2 that started in 2025, is one of 3 observational ones, and was the 58th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →1 of the 60 studies in Parkinson Disease by Bial - Portela C S.A. is open now, in 1 country.
By country, each count listing its studies:
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is close to the median of 96 across 1,086 observational studies indexed under Parkinson Disease.
Median enrollment 28 across the 56 interventional studies, 90 across the 3 observational. Of the 57 that completed or were terminated, 27 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bial - Portela C S.A. is the lead sponsor of 136 studies on the registry; 1 is open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 60 studies in Parkinson Disease by Bial - Portela C S.A., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to generate real-world evidence data for the on-demand treatment with SL-APO, focusing on understanding its usage and titration practices including individual dose determination after dose-adjustment to ultimately understand their influence in patient satisfaction, treatment persistence, and the balance between effectiveness and safety. The data may help optimize titration approaches to better meet the patient's needs.
This study is a prospective, observational, real-word evidence study. It is a non-interventional study according to article 2(4) of the Clinical Trials Regulation. Visits are documented as they occur in the routine of the practice or PD clinic.
The medical evaluation that leads to a treatment plan for the patient is not part of this study. The treatment plan may not include SL-APO. This study protocol becomes relevant only after unbiased prescription of SL-APO. Under no circumstances will access to treatment be contingent upon participation in the study. No additional procedures or examinations are required besides the ones already performed per local medical practice.
Patients who will initiate SL-APO according to the SmPC are potential study patients. After the patient's consent to participate in the study, the study starts with the baseline visit at the site (dark blue icon). The tolerance and efficacy of 10 mg SL-APO is tested for a patient in the OFF-state. In case of an insufficient "ON"-response of the first 10 mg dose, dose finding continues with titration at home (light blue house). The Titration follow-up (FU) takes place during the dose finding phase preferably when the patient has reached the preferred dose. The Titration FU can take place as a call or on-site. If a patient is not in the optimal dose during the Titration FU, they will be called again, as per their practice routine. Note, the only data collected from the Titration FU is if the optimal dose according to the HCP has been reached (and the date of the call). Patients will keep a Patient Titration Diary from the baseline visit to the end of titration. The diary entries are started from the 2nd intake of SL-APO. This is regardless of whether the intake takes place at home or in the clinical environment. Patients will keep a Patient Maintenance Diary after the end of titration until the end of the study. For at least the first 7 days and a minimum of 10 intakes, the Patient Maintenance Diary is kept daily, followed by a weekly entry. At 3 and 6 months, FU visits take place at the site. The 6-month FU visit marks the end of the study. The Investigator will decide if patients should continue to be prescribed the maintenance dose after the end of the trial.
Adult patients experiencing OFF symptoms which cannot be managed by oral anti-PD medication. For clarification, patients who have previously been exposed to apomorphine can also be included in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SL-APO is available as a treatment initiation pack, containing two sublingual films of each strength (total of 30 films). The treatment initiation pack is usually used at the start of treatment to find an effective and tolerable dose. Depending on the patient response, not all doses in this pack may be needed.
Drug: SL-APO
Patients should start with a dose of 10 mg SL-APO. Dose initiation should occur when the patient is having an OFF episode. If the patient tolerates the 10 mg dose, and responds adequately (meaning satisfactory motor response within 30 minutes), the maintenance dose should be 10 mg. If the dose is tolerated but the response is insufficient, continue to titrate in 5 mg increments when the patient is having an OFF episode and assess response until an effective and tolerable dose is achieved, up to a maximum of 30 mg per dose and up to five times a day. If an "ON" response is achieved and if clinically warranted, consider the need to further up-titrate as tolerated to achieve a better "ON" response. The minimal interval between doses is 2 hours, with no more than one dose of SL-APO per OFF episode.
Also known as: Kynmobi
Identify the most frequent dose used after dose-adjustment
The purpose of the study is to generate real-world evidence data for the on-demand treatment with SLAPO, focusing on understanding its usage and titration practices including individual dose determination after dose-adjustment to ultimately understand their influence in patient satisfaction, treatment persistence, and the balance between effectiveness and safety. The data may help optimize titration approaches to better meet the patient's needs.
Time frame: Up to 6 months
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Feb 2028, 30 months after the start.
Of 60 industry-sponsored observational studies under Parkinson Disease, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 30 months is below that.
Counting every sponsor, half of 439 studies reached it within 47 months; a quarter within 22 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.